RxDoctor Payments Data

Shane Stone, MD

Family Medicine · Denton, TXNPI 1104054295

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 12 payments — averaging $92.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$720
  • Avanir Pharmaceuticals, Inc.$203
  • Amgen$95
  • AbbVie$42
  • E.r. Squibb & Sons, L.L.C.$20
  • Supernus Pharmaceuticals, Inc.$17
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,108 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$8,065,360
Medicare patients
14,238
Services billed
170,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$42,519
JardianceEmpagliflozin28$26,041
OzempicSemaglutide16$24,568
EliquisApixaban16$12,090
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen267$8,850
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$7,101
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,735
Gabapentin114$2,222
SynthroidLevothyroxine Sodium15$1,310
Hydroxychloroquine Sulfate19$1,215
Dextroamphetamine Sulfate12$1,185
Pregabalin44$1,051
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$962
Dicyclomine Hcl11$776
Levothyroxine Sodium85$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$12$42,51925 claims
AbbVieSynthroid$42$1,31015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →